Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06550011 · ClinicalTrials.gov registry record · Phase 1
Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Intravitreal (IVT) Injection of ABI-110 (AAV2.N54-VEGF Trap) in Subjects With Neovascular (Wet) Age-Related Macular Degeneration (wAMD), Including Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV)
A Phase 1 study of Neovascular (Wet) AMD, sponsored by Avirmax Biopharma.
- Active
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 4
- Study locations
NCT06550011 is a Phase 1 study of Neovascular (Wet) AMD that is active but no longer recruiting, run by Avirmax Biopharma. The registered enrollment target is 18 participants. The trial reports 4 study locations across 2 states.
The verdict
NCT06550011, a Phase 1 study of Neovascular (Wet) AMD, is active but no longer recruiting, sponsored by Avirmax Biopharma.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 4
- Study locations
Study Summary
This will be a clinical study to assess initial safety and tolerability of IVT ABI-110 in patients diagnosed with wet macular degeneration (wAMD), including symptomatic macular PCV.
Conditions Studied
Interventions
- DRUG ABI-110 Low Dose
- DRUG ABI-110 Medium Dose
- DRUG ABI-110 High Dose
Study Locations (4)
California
- California Retina Consultants - Bakersfield
- Bay Area Retina Associates - Walnut Creek
Texas
- Retina Consultants of Texas - San Antonio - San Antonio
- Retina Consultants of Texas - The Woodlands
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2024-08-07 |
| Est. Completion | 2031-01-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06550011
The ClinicalTrials.gov registry entry for NCT06550011 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Avirmax Biopharma, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neovascular (Wet) AMD appearing as the primary indexed condition, and to 3 interventions - of which ABI-110 Low Dose is the first listed.
NCT06550011 reports 4 study locations spanning 2 distinct geographic areas - top geographies include California, Texas.
Frequently Asked Questions
What is clinical trial NCT06550011 about?
NCT06550011 is a clinical study titled "Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Intravitreal (IVT) Injection of ABI-110 (AAV2.N54-VEGF Trap) in Subjects With Neovascular (Wet) Age-Related Macular Degeneration (wAMD), Including Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV)". This will be a clinical study to assess initial safety and tolerability of IVT ABI-110 in patients diagnosed with wet macular degeneration (wAMD), including symptomatic macular PCV.
What is the current status of trial NCT06550011?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2024-08-07. Estimated completion is 2031-01-16.
What conditions does trial NCT06550011 study?
This clinical trial studies the following conditions: Neovascular (Wet) AMD.
What interventions are being tested in trial NCT06550011?
The interventions under investigation include: ABI-110 Low Dose (DRUG), ABI-110 Medium Dose (DRUG), ABI-110 High Dose (DRUG).
Who is sponsoring clinical trial NCT06550011?
This trial is sponsored by Avirmax Biopharma, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06550011 being conducted?
This trial has 4 study locations across California, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.